Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · IEX Real-Time Price · USD
19.66
+0.13 (0.67%)
At close: Feb 26, 2024, 4:00 PM
19.75
+0.09 (0.46%)
Pre-market: Feb 27, 2024, 7:37 AM EST
0.67%
Market Cap 1.79B
Revenue (ttm) 117.00M
Net Income (ttm) -307.00M
Shares Out 90.86M
EPS (ttm) -4.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,014,382
Open 19.50
Previous Close 19.53
Day's Range 19.28 - 20.17
52-Week Range 12.95 - 25.47
Beta 0.78
Analysts Strong Buy
Price Target 41.78 (+112.51%)
Earnings Date Feb 21, 2024

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclust... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 15, 2018
Employees 577
Stock Exchange NYSE
Ticker Symbol RCUS
Full Company Profile

Financial Performance

In 2023, RCUS's revenue was $117.00 million, an increase of 4.46% compared to the previous year's $112.00 million. Losses were -$307.00 million, 15.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is $41.78, which is an increase of 112.51% from the latest price.

Price Target
$41.78
(112.51% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

5 days ago - Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

17 days ago - Business Wire

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

19 days ago - Business Wire

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer ...

Other symbols: GILD
4 weeks ago - Reuters

Gilead and Arcus Announce Amended Collaboration and Equity Investment

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and ...

Other symbols: GILD
4 weeks ago - Business Wire

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. ARC-...

5 weeks ago - Business Wire

20 favorite small-cap stocks for 2024 among Wall Street analysts

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...

2 months ago - Market Watch

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

ALAMEDA, Calif. and HAYWARD, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration...

Other symbols: EXEL
3 months ago - Business Wire

From laggards to leaders: Small caps on the rise

Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, bu...

3 months ago - MarketBeat

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

3 months ago - Business Wire

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

3 months ago - Business Wire

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemother...

Other symbols: GILD
4 months ago - Business Wire

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemothera...

Other symbols: GILD
4 months ago - Business Wire

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Cl...

4 months ago - Business Wire

Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

6 months ago - Business Wire

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,...

Other symbols: GILDRHHBYITOS
6 months ago - Market Watch

Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

7 months ago - Business Wire

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RC...

Other symbols: ALVRGILD
8 months ago - MarketBeat

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the A...

Other symbols: GILD
9 months ago - Business Wire

Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

9 months ago - Business Wire

Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences' Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

10 months ago - Business Wire

Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously ann...

Other symbols: GILD
10 months ago - Business Wire

Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

10 months ago - Business Wire

Arcus Biosciences to Participate in the Barclays Global Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...

1 year ago - Business Wire

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

1 year ago - Business Wire